HIV-1 prevalence in Guangxi, China, has been growing since 1996, when the first case was reported. Over half of HIV-1 positive patients in Guangxi Province were injecting drug users (IDUs), possibly because of the province’s location near drug-trafficking routes. Since a phase II HIV vaccine trial is ongoing there, a current characterization of the subtypes of HIV-1 among IDUs in Guangxi would provide critical information for future HIV vaccine trials, as well as further control and prevention of HIV-1 transmission. Thus, we conducted a molecular epidemiological investigation of HIV-1 samples from 2008–2010 among IDUs in multiple cities in Guangxi Province. Our results, based on the gag/pol fragment, indicated a very high proportion (78.47%) of HIV-1 CRF08_BC recombinants, some CRF01_AE (15.38%) recombinants, and a low proportion of CRF07_BC (6.15%) recombinants among the IDUs. The high proportion of CRF08 HIV-1 strains among recent IDUs matches the vaccine candidate constructs. However, future vaccine development should also incorporate CRF01-targeted vaccine candidates. Distinct Env sequence evolution patterns were observed for CRF08_BC and CRF01_AE, indicating that different local selection pressures have been exerted on these two HIV-1 subtypes. Unique drug-resistant mutations were also detected, and our data indicate that HIV treatment programs should consider pre-existing drug-resistant mutations.
References
[1]
Skar H, Hedskog C, Albert J (2011) HIV-1 evolution in relation to molecular epidemiology and antiretroviral resistance. Ann N Y Acad Sci 1230: 108–118.
[2]
Teng T, Shao Y (2011) Scientific approaches to AIDS prevention and control in China. Adv Dent Res 23: 10–12.
[3]
Beyrer C, Razak MH, Lisam K, Chen J, Lui W, et al. (2000) Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. Aids 14: 75–83.
[4]
Garten RJ, Lai S, Zhang J, Liu W, Chen J, et al. (2004) Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 33: 182–188.
[5]
Garten RJ, Zhang J, Lai S, Liu W, Chen J, et al. (2005) Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 41 Suppl 1S18–24.
[6]
Yu XF, Chen J, Shao Y, Beyrer C, Lai S (1998) Two subtypes of HIV-1 among injection-drug users in southern China. Lancet 351: 1250.
[7]
Yu XF, Chen J, Shao Y, Beyrer C, Liu B, et al. (1999) Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. J Acquir Immune Defic Syndr 22: 180–188.
[8]
Piyasirisilp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, et al. (2000) A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol 74: 11286–11295.
[9]
Yu ES, Xie Q, Zhang K, Lu P, Chan LL (1996) HIV infection and AIDS in China, 1985 through 1994. Am J Public Health 86: 1116–1122.
[10]
Laeyendecker O, Zhang GW, Quinn TC, Garten R, Ray SC, et al. (2005) Molecular epidemiology of HIV-1 subtypes in southern China. J Acquir Immune Defic Syndr 38: 356–362.
[11]
Zeng H, Sun Z, Liang S, Li L, Jiang Y, et al. (2012) Emergence of a New HIV Type 1 CRF01_AE Variant in Guangxi, Southern China. AIDS Res Hum Retroviruses 28: 1352–1356.
[12]
Su Q, Liang H, Cen P, Bi Z, Zhou P (2012) HIV type 1 subtypes based on the pol gene and drug resistance mutations among antiretroviral-naive patients from Guangxi, Southern China. AIDS Res Hum Retroviruses 28: 725–728.
[13]
Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731–2739.
[14]
Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, et al. (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73: 152–160.
[15]
Bon I, Alessandrini F, Borderi M, Gorini R, Re MC (2007) Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. New Microbiol 30: 313–317.
[16]
Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC (1994) Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis 170: 1292–1295.
[17]
Pang W, Zhang C, Duo L, Zhou YH, Yao ZH, et al. (2012) Extensive and complex HIV-1 recombination between B’, C and CRF01_AE among IDUs in south-east Asia. AIDS 26: 1121–1129.
[18]
McClutchan FE, Carr JK, Murphy D, Piyasirisilp S, Gao F, et al. (2002) Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. AIDS Res Hum Retroviruses 18: 1135–1140.
[19]
Song YH, Meng ZF, Xing H, Ruan YH, Li XP, et al. (2007) Analysis of HIV-1 CRF07_BC gag p6 sequences indicating novel deletions in the central region of p6. Arch Virol 152: 1553–1558.
[20]
Yu XF, Liu W, Chen J, Kong W, Liu B, et al. (2002) Maintaining low HIV type 1 env genetic diversity among injection drug users infected with a B/C recombinant and CRF01_AE HIV type 1 in southern China. AIDS Res Hum Retroviruses 18: 167–170.
[21]
Tripathy S, Renjifo B, Wang WK, McLane MF, Bollinger R, et al. (1996) Envelope glycoprotein 120 sequences of primary HIV type 1 isolates from Pune and New Delhi, India. AIDS Res Hum Retroviruses 12: 1199–1202.
[22]
Shang H, Zhong P, Liu J, Han X, Dai D, et al. (2010) High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China. PLoS One 5: e10631.
[23]
Liu J, Zhang C (2011) Phylogeographic analyses reveal a crucial role of Xinjiang in HIV-1 CRF07_BC and HCV 3a transmissions in Asia. PLoS One 6: e23347.
[24]
Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA (1991) Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A 88: 3195–3199.
[25]
Yu XF, Matsuda Z, Yu QC, Lee TH, Essex M (1995) Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation. J Gen Virol 76 (Pt 12): 3171–3179.
[26]
Yu XF, Dawson L, Tian CJ, Flexner C, Dettenhofer M (1998) Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J Virol 72: 3412–3417.
[27]
Dettenhofer M, Yu XF (1999) Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. J Virol 73: 4696–4704.
[28]
Zhefeng M, Huiliang H, Chao Q, Jun S, Jianxin L, et al. (2011) Transmission of new CRF07_BC strains with 7 amino acid deletion in Gag p6. Virol J 8: 60.
